Patient-derived tumour xenografts as models for oncology drug development
about
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted TherapyPatient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic reviewMouse Models in Prostate Cancer Translational Research: From Xenograft to PDXBioengineering Models for Breast Cancer ResearchAn Integrative Approach to Precision Cancer Medicine Using Patient-Derived XenograftsCurrent State of Animal (Mouse) Modeling in Melanoma ResearchMolecular and clinical implementations of ovarian cancer mouse avatar modelsUse of rodents as models of human diseasesPatient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatmentThe role of surgeons in building a personalized medicine programEarly phase clinical trials to identify optimal dosing and safetyOne mouse, one patient paradigm: New avatars of personalized cancer therapyContemporary murine models in preclinical astrocytoma drug developmentCurrent status and evolution of preclinical drug development models of epithelial ovarian cancerLabel-free DNA imaging in vivo with stimulated Raman scattering microscopy.Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenograftsPreclinical mouse cancer models: a maze of opportunities and challenges.Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid CulturesDual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancerMdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cellsSystems biology approaches for advancing the discovery of effective drug combinationsA natural small molecule, catechol, induces c-Myc degradation by directly targeting ERK2 in lung cancerStimulated Raman scattering microscopy: an emerging tool for drug discoveryPatient-derived xenografts: a relevant preclinical model for drug developmentAnti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan)Pharmacogenetics and pharmacogenomics as tools in cancer therapyOrganoid development in cancer genome discoveryPrioritizing therapeutic targets using patient-derived xenograft modelsImaging tumor metabolism using positron emission tomographyFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentXenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot studyEstablishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenograftsIntegrated analysis of transcriptome in cancer patient-derived xenograftsMetformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived XenograftsA Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsIn vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft.Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma.Erlotinib inhibits growth of a patient-derived chordoma xenograft.The future of patient-derived tumor xenografts in cancer treatment.
P2860
Q21131727-CDEA5CAC-5746-43A7-B313-DD7C55DB17C2Q26741651-ADDDDD7A-765C-49F9-A728-E9F51A4E25B3Q26746524-01ACCEE8-064E-4228-8EE3-9E9B08071F4AQ26770495-B94E4BEA-1484-4250-AEA8-E7840304EF2FQ26772895-E290F547-0EF5-43A2-8260-6CB78ACBD90AQ26781652-57E7BDDE-188E-47D2-95E2-B472E18B6DC2Q26786724-5585ACB8-DFEF-4390-B651-4DB48C1F9501Q26822856-7B8F9B3F-A959-4957-BED1-4ABA8B8E5946Q26829125-5788D656-6BEA-4BCB-AE48-013F05606F90Q26849667-8224CE30-6311-4118-81C8-5B97B1CB1EB3Q26865076-A2822E13-D6F6-454C-A9E5-FC3DE8F21078Q27023342-6E3B6040-5B56-4A22-9473-C94C068A06C9Q27026937-989761C4-27E7-4BC6-8005-0A08F55EF7B5Q27028117-408A5438-47AE-4305-9657-66B0E4AD1A69Q27318691-E82335F8-997C-4C5F-B536-022B0A6280B2Q27321370-155CD7D5-D6A0-4F5B-B0ED-A64BBF36934AQ27322080-55FED839-530A-4635-B325-89D452EE5939Q27324252-F9B369DE-E312-4B5D-AC22-2C3EC44B8741Q27324821-475D4F7C-FE82-4906-9C34-CA810FBBE399Q27347800-00B7DC45-0809-4809-B572-92B7099CFA8FQ27702922-38AF5CAA-89BB-40C7-9C68-379654C921FCQ27704839-BCDAA626-3B83-4A65-AA85-CEF35D76A0DDQ28067096-C6091494-7BFF-40A8-87A0-66514FB54559Q28067191-322F7F99-946E-49C5-BAD0-CF2D9D95E6F9Q28074630-9A408AE6-6EC2-471F-B591-9116A2E661ADQ28076200-E3439ADA-A1BB-454D-AF77-2523D131A75DQ28083032-08F7EBAE-DEB8-4C91-AAC5-24A24281F0F3Q28083993-F64067BF-A214-473E-9AD9-7369898065F0Q28085278-007C6F58-85AF-4989-A307-1D1754BC2C96Q28533949-83293E04-0816-43E0-961D-DA22AAF107F8Q28538185-E2A2F380-AD50-4E2E-B73B-F472277261CEQ28538581-C14359DD-97BD-4BD6-8C2D-C204ECBC6DA4Q28547069-F8503D9F-9631-4A63-A546-8310EA53634BQ28552408-01DF8803-53AA-4685-9701-D8F8CE07D61FQ28598343-E5A06A38-71D8-4E33-B525-47F6F63FFF45Q30372076-64E13E0A-06EF-419F-B3A8-5F310AEBF228Q30423597-82A5E84F-CA82-4517-AEE9-519E23E505BFQ30557486-DC4CF586-98A3-4E25-AD71-68DAC905A380Q33275026-98A8A957-DDB7-4E0B-9FCC-202FE6EBD598Q33361578-BB09739E-6BD6-42F7-AF0B-AD40521ED14F
P2860
Patient-derived tumour xenografts as models for oncology drug development
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Patient-derived tumour xenografts as models for oncology drug development
@ast
Patient-derived tumour xenografts as models for oncology drug development
@en
Patient-derived tumour xenografts as models for oncology drug development
@nl
type
label
Patient-derived tumour xenografts as models for oncology drug development
@ast
Patient-derived tumour xenografts as models for oncology drug development
@en
Patient-derived tumour xenografts as models for oncology drug development
@nl
prefLabel
Patient-derived tumour xenografts as models for oncology drug development
@ast
Patient-derived tumour xenografts as models for oncology drug development
@en
Patient-derived tumour xenografts as models for oncology drug development
@nl
P2093
P2860
P3181
P1476
Patient-derived tumour xenografts as models for oncology drug development
@en
P2093
Antonio Jimeno
Colin D Weekes
John J Arcaroli
John J Tentler
S Gail Eckhardt
Stephen Leong
Todd M Pitts
Wells A Messersmith
P2860
P2888
P304
P3181
P356
10.1038/NRCLINONC.2012.61
P407
P577
2012-04-17T00:00:00Z
P6179
1013064241